AgingResearch.NewsJoin free

No phaseRecruitingGeroscience intervention

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Sponsor
Scott Silveira (Academic or other)
Enrollment
40 planned
Conditions
Aging; Frailty; Exercise Tolerance; Healthy Male and Female Subjects
Interventions
NMN and TMG (Euexia); Nicotinamide Mononucleotide (NMN); Placebo
Ages
adults, older adults
Registry
NCT07144527

Full record on ClinicalTrials.gov

From the registry

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. The supplements have been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Primary outcomes

  • Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM).

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered